One of the biggest trends in the fight against obesity has been the explosion in popularity of GLP-1 medications. Created to treat diabetes, patients who were prescribed the popular GLP-1 drugs Ozempic,…
Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9. The telehealth company pulled its copycat semaglutide weight-loss pill over the weekend after threats of legal…
Hims & Hers Health (NASDAQ: HIMS) has had among the worst runs of any public company over the last year. And, there is little reason to think it will recover. The stock…
Hims & Hers (NYSE:HIMS) shares are plunging 16% in after-hours trading following coordinated moves by two federal agencies against its compounded weight-loss drugs. The Food and Drug Administration (FDA) announced plans to…
Rich Duprey Pre-Market Stock Futures: The futures are trading lower on Monday morning after a strong finish to the week on Friday, completing a winning week for investors as all three of the major…
Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty telehealth platform offering prescription medications, mental health support, and personal care products.…
William Temple Live Updates What We Learned From the Quarterly Conference call 6:04pm ETThe call centered around Hims & Hers’ push beyond treatment into proactive and personalized health management. Dudum confirmed plans to launch…
Joel South A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO | NVO Price Prediction) has been a trailblazer in the GLP-1 drug market, revolutionizing diabetes and obesity treatment with its blockbuster…
Weighing the Options The introduction of Novo Nordisk’s (NYSE:NVO | NVO Price Prediction) Ozempic revolutionized the fight against obesity, shifting the narrative from lifestyle interventions to pharmacological solutions. Glucagon-like peptide-1 (GLP-1) receptor…
Live Updates Tuesday Wrap-up4:27pm ETThe Vanguard S&P 500 ETF closed at 577.35 Tuesday, down 0.5%. Getting the DUKs in a Row12:41pm ETS&P component company Duke Energy (NYSE: DUK | PFE Price Prediction) beat…
Live Updates Conference Cal Starts in 10 Minutes 4:50pm ETWe’ll post a summary of the call later. Simply leave this page open and if you check later a new update with our…
Joel South Danish pharmaceutical giant Novo Nordisk (NYSE:NVO | NVO Price Prediction) is watching its stock plummet 20% in morning trading after slashing its full-year sales and profit outlook for the second time this…
Telehealth platform Hims & Hers Health (NYSE:HIMS) shot to the top of stock charts yesterday as shares soared 16% high on no company news. While it is revolutionizing access to healthcare by…
Digging Into the Bargain Bin Investing in beaten-down stocks can be a savvy strategy for long-term wealth creation, as it allows investors to buy high-quality companies at bargain prices. When market sentiment…
If you wish to turn $10,000 into $50,000 by 2035, you’re looking at a 400% gain over a 10-year horizon. In the past decade, the S&P 500 has gained 194%, and the…
